Copyright
©2011 Baishideng Publishing Group Co.
World J Cardiol. Nov 26, 2011; 3(11): 367-373
Published online Nov 26, 2011. doi: 10.4330/wjc.v3.i11.367
Published online Nov 26, 2011. doi: 10.4330/wjc.v3.i11.367
Table 1 Charlson comorbidity index components and weights
Comorbid condition | Weight |
Myocardial infarction | 1 |
Congestive heart failure | 1 |
Peripheral vascular disease | 1 |
Cerebrovascular disease | 1 |
Dementia | 1 |
Chronic pulmonary disease | 1 |
Connective tissue disease | 1 |
Ulcer disease | 1 |
Mild liver disease | 1 |
Diabetes | 1 |
Hemiplegia | 2 |
Moderate or severe renal disease | 2 |
Diabetes with end-organ damage | 2 |
Any tumor | 2 |
Leukemia | 2 |
Lymphoma | 2 |
Moderate or severe liver disease | 3 |
Metastatic solid tumor | 6 |
AIDS | 6 |
Table 2 Baseline clinical characteristics of the study population (n = 138)
n (%) | |
Age (mean ± SD, yr) | 70.7 ± 9.3 |
Female | 29 (21.0) |
Hypertension | 95 (68.8) |
Diabetes mellitus | 44 (31.8) |
Dyslipidemia | 73 (52.9) |
Smoking | 34 (24.6) |
Renal failure | 30 (21.7) |
Previous stroke | 25 (18.1) |
Vasculopathy | 22 (15.9) |
Previous coronary artery bypass graft | 32 (23.1) |
Previous percutaneous coronary intervention | 21 (15.2) |
Previous myocardial infarction | 46 (33.3) |
Charlson score (mean ± SD) | 4.3 ± 1.6 |
Clinical presentation | |
Asymptomatic | 12 (8.7) |
Stable angina | 45 (32.6) |
NSTEMI | 58 (42.0) |
STEMI | 21 (15.2) |
Indication to AVK treatment | |
Atrial fibrillation | 93 (67) |
CHADS2 0 | 0 (0) |
CHADS2 1 | 69 (75) |
CHADS2 ≥ 2 | 24 (25) |
Pulmonary emboli | 4 (2.9) |
Systemic emboli | 4 (2.9) |
Isolated cardiomyopathy | 14 (10.1) |
Mechanical valve prosthesis | 22 (15.2) |
Thrombus in left ventricle | 2 (1.4) |
Number of diseased vessels | |
1 | 79 (57.2) |
2 | 41 (29.7) |
3 | 16 (11.6) |
Number of treated vessels | |
1 | 118 (85.5) |
2 | 20 (14.5) |
Vessels diseased | |
Left main | 13 |
Left anterior descending | 85 |
Left circumflex | 52 |
Right coronary artery | 69 |
Saphenous vein graft | 4 |
Table 3 Angiographic and procedural characteristics (n = 178) n (%)
Lesion type classification | |
A | 40 (23.1) |
B | 103 (59.5) |
C | 25 (17.4) |
Chronic total occlusion | 9 (5.2) |
Bifurcation | 30 (17.3) |
Access site | |
Transradial | 133 (74.8) |
Transfemoral | 52 (25.2) |
Direct stenting | 45 (25.3) |
DES | 26 (14.6) |
Length of implanted stents (mm, mean ± SD) | 22.3 ± 11.6 |
Diameter of implanted stents (mm, mean ± SD) | 3.18 ± 1.24 |
QCA analysis (mean ± SD) | |
Reference diameter pre (mm) | 2.9 ± 0.67 |
Reference diameter post (mm) | 3.0 ± 0.55 |
MLD pre (mm) | 0.74 ± 0.5 |
MLD post (mm) | 2.6 ± 0.5 |
% stenosis pre | 74.6 ± 16.1 |
% stenosis post | 12.3 ± 8.9 |
Acute gain (mm) | 1.8 ± 0.6 |
Table 4 Long-term clinical outcomes after discharge (1n = 178)
n (%) | |
Major adverse cardiac events | 31 (22.9) |
Death | 21 (15.5) |
Cardiac death | 17 (12.6) |
Non-cardiac death | 4 (2.9) |
Myocardial infarction | 8 (5.9) |
Target lesion revascularization | 15 (11.1) |
Major hemorrhagic event | 10 (7.4) |
Stroke | |
Hemorrhagic stroke | 3 (2.2) |
Ischemic stroke | 2 (1.5) |
Definite/probable stent thrombosis | 6 (4.4) |
Possible stent thrombosis | 8 (5.9) |
- Citation: Brugaletta S, Martin-Yuste V, Ferreira-González I, Cola C, Alvarez-Contreras L, Antonio MD, Garcia-Moll X, García-Picart J, Martí V, Balcells-Iranzo J, Sabaté M. Adequate antiplatelet regimen in patients on chronic anti-vitamin K treatment undergoing percutaneous coronary intervention. World J Cardiol 2011; 3(11): 367-373
- URL: https://www.wjgnet.com/1949-8462/full/v3/i11/367.htm
- DOI: https://dx.doi.org/10.4330/wjc.v3.i11.367